Return on Equity (ROE)
Updated 224h ago
Sector Performance
90th percentileCDW
44.2%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how efficiently a company converts shareholder equity into profit; CDW’s current ROE of 44.2% means it generates $0.442 of profit for every dollar of equity.
That figure far exceeds the sector median of 13.8%, placing CDW in the 89th percentile among its peers. Year-over-year and quarter-over-quarter changes are both listed as N/A, and no trend direction is available for the last eight quarters. The combination of a very high ROE with no trend data creates uncertainty: the level indicates strong current profitability, but the absence of historical movement prevents any judgment about whether that performance is stable or deteriorating. This metric supports the overall NEUTRAL verdict because while the ROE level is excellent, the lack of trend information and the platform’s broader assessment suggest other factors temper the outlook.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about CDW?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are CDW's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master CDW's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CDW research report →CDW
44.2%
Sector Median
13.8%
Sector Avg
31.4%
How CDW's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.